Emerging drugs for renal cell carcinoma

Bibliography

• Gnarra JR, Tory K, Weng Y, Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373(9669):1119-32
   PubMed Web of Science ®Google Scholar
• Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008;35(4):687-701; ix
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 2003;30(3):601-9, x
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96
   PubMed Web of Science ®Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55-7
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338(18):1272-8
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Carteni G, Autorino R, Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
   PubMed Web of Science ®Google Scholar
• Garcia JA, Hutson TE, Elson P, Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010; In press
   Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
   PubMed Web of Science ®Google Scholar
• Patyna S, Laird AD, Mendel DB, SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5(7):1774-82
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM, Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels JP, Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(3):475-80
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010;28(6):1061-8
   Google Scholar
• Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14(5):1286-90
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Giessinger S, A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115(11):2438-46
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14(22):7272-83
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taguchi E, Miura T, KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66(18):9134-42
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. J Clin Oncol 2010;28(5):780-7
   Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462-8
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736) [abstract]. J Clin Oncol 2008;26(20 Suppl):3543
   PubMed Web of Science ®Google Scholar
• Garcia JA, Hudes G, Choueiri TK, Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). Genitourinary Cancers Symposium 2010: Abstract 326.
   Google Scholar
• Bhargava P, Esteves B, Nosov DA, Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2009;27(15 Suppl):5032
   Web of Science ®Google Scholar
• Tew WP, Gordon M, Murren J, Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16(1):358-66
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Rothenberg ML, Dupont J, Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28(2):207-14
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-25
   PubMed Web of Science ®Google Scholar
• Qian F, Engst S, Yamaguchi K, Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69(20):8009-16
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Choueiri TK, Vaishampayan U, A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2008;26(Suppl): abstract 5103
   Google Scholar
• Garcia A, Rosen L, Cunningham CC, Phase I study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase II dose [abstract]. J Clin Oncol 2007;25(18 Suppl):3525
   PubMed Web of Science ®Google Scholar
• Mekhail T, Rich T, Rosen L, Final results: A dose escalation phase I study or ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors [abstract]. J Clin Oncol 2009;27(15 Suppl):3548
   Web of Science ®Google Scholar
• Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 2009;11(4):448-55
   PubMed Web of Science ®Google Scholar
• Gordon MS, Sweeney CS, Mendelson DS, Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16(2):699-710
   PubMed Web of Science ®Google Scholar
• Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007;5(7):655-65
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16
   PubMed Web of Science ®Google Scholar
• Imanishi Y, Hu B, Jarzynka MJ, Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res 2007;67(9):4254-63
   PubMed Web of Science ®Google Scholar
• Hollborn M, Stathopoulos C, Steffen A, Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 2007;48(9):4360-7
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
   PubMed Web of Science ®Google Scholar